

## **REGISTERED OFFICE**

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471

## Dated August 22, 2019

To,

National Stock Exchange of India Limited

**BSE** Limited

Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules Pharmaceuticals, Inc. completed U.S. FDA inspection.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, US FDA has completed inspection of the facility of Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA on 21<sup>st</sup> August 2019 with two (2) minor observations. This is a preapproval inspection for seven products filed from this facility. Granules Pharmaceuticals, Inc. will respond to these observations within the stipulated time period.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

CHAITANYA TUMMALA (COMPANY SECRETARY &

**COMPLIANCE OFFICER)**